ONCS - オンコセク・メディカル （OncoSec Medical Incorporated） オンコセク・メディカルONCSのチャート
ONCSの企業情報
| symbol | ONCS |
|---|---|
| 会社名 | OncoSec Medical Inc （オンコセク・メディカル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate ImmunoPulse IL-12 consists of a plasmid construct encoding the proinflammatory cytokine IL-12 which is delivered into the tumor through in vivo electroporation. As of July 31 2016 the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced metastatic melanoma. In addition it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology which is designed to stimulate the human immune system resulting in systemic anti-tumor immune responses. オンコセク・メディカルは米国のバイオテクノロジ―企業。固形腫瘍の治療のための医療的アプロ―チ（主に免疫療法）の発見、開発、実用化に従事する。同社の治験プラットフォ―ムであるImmunoPulsは、DNAに基づく治療薬を直接的に腫瘍に局所送達および取り込みを行うように設計されている。2011年設立、本社はサンディエゴ。 OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. |
| 本社所在地 | 3565 General Atomics Court Suite 100 San Diego CA 92121 USA |
| 代表者氏名 | Avtar S. Dhillon Avtar S. Dhillon |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-210-7333 |
| 設立年月日 | 39479 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 35人 |
| url | www.oncosec.com |
| nasdaq_url | https://www.nasdaq.com/symbol/oncs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.01532 |
| 終値（lastsale） | 1.59 |
| 時価総額（marketcap） | 83227931.49 |
| 時価総額 | 時価総額（百万ドル） 84.27482 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 53.99075 |
| 当期純利益 | 当期純利益（百万ドル） -32.59503 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 April 2018 OncoSec Medical Inc revenues was not reported. Net loss increased 72% to $26.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.79 to -$0.77. |
ONCSのテクニカル分析
ONCSのニュース
Investing in OncoSec Medical Incorporated (ONCS) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/04 14:48:00 US Post News
A share of OncoSec Medical Incorporated (NASDAQ:ONCS) closed at $2.08 per share on Tuesday, up from $1.68 day before. While OncoSec Medical Incorporated has overperformed by 23.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ONCS fell by -90.15%, with highs and lows ranging from $31.90 […]
OncoSec Medical Incorporated (ONCS) Is A Buy Stock For Small Caps – Analysts 2023/01/04 13:00:00 Marketing Sentinel
OncoSec Medical Incorporated (NASDAQ:ONCS) has a beta value of 1.57 and has seen 1.84 million shares traded in the last trading session. The company, currently valued at $6.80M, closed the last trade at $2.08 per share which meant it gained $0.4 on the day or 23.81% during that session. The ONCS stock price is -1433.65% … OncoSec Medical Incorporated (ONCS) Is A Buy Stock For Small Caps – Analysts Read More »
Was anything positive for OncoSec Medical Incorporated (ONCS) stock last session? 2022/12/22 12:00:00 US Post News
OncoSec Medical Incorporated (NASDAQ:ONCS) marked $1.87 per share on Wednesday, up from a previous closing price of $1.61. While OncoSec Medical Incorporated has overperformed by 16.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ONCS fell by -92.54%, with highs and lows ranging from $31.90 to […]
OncoSec Medical Incorporated (NASDAQ:ONCS) Is Currently -1765.5% Below Its 52-Week High, But Downside Potential Could Surprise You. 2022/12/17 13:00:00 Marketing Sentinel
In last trading session, OncoSec Medical Incorporated (NASDAQ:ONCS) saw 0.36 million shares changing hands with its beta currently measuring 1.52. Company’s recent per share price level of $1.71 trading at -$0.03 or -1.72% at ring of the bell on the day assigns it a market valuation of $3.54M. That closing price of ONCS’s stock is … OncoSec Medical Incorporated (NASDAQ:ONCS) Is Currently -1765.5% Below Its 52-Week High, But Downside Potential Could Surprise You. Read More »
Peering Into OncoSec Medical''s Recent Short Interest 2022/12/08 13:23:44 Benzinga
OncoSec Medical''s (NASDAQ: ONCS ) short percent of float has risen 16200.0% since its last report. The company recently reported that it has 16 thousand shares sold short , which is 1.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Horizon, Check-Cap top healthcare gainers; Aeglea, OncoSec lead losers pack 2022/11/30 15:02:35 Seeking Alpha
Horizon Therapeutics HZNP +28%. Check-Cap (CHEK) +14%. Aeglea BioTherapeutics AGLE -61%. OncoSec Medical ONCS -22%.
OncoSec Medical prices $3.5M stock offering (NASDAQ:ONCS) 2022/11/30 14:36:38 Seeking Alpha
OncoSec Medical (ONCS) on Wednesday has priced its stock offering of 1.167M shares and accompanying warrants at $3 each. That is to amount the gross proceeds of about…
Thinking about buying stock in Apollo Endosurgery, OncoSec Medical, Cosmos Holdings, Zhihu, or Bilibili? 2022/11/29 13:34:00 Benzinga
NEW YORK , Nov. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APEN, ONCS, COSM, ZH, and BILI. … Full story available on Benzinga.com
OncoSec Medical Incorporated (NASDAQ:ONCS) Falls -4.85%, But An Additional Plunge May Follow. 2022/11/25 12:30:00 Marketing Sentinel
In last trading session, OncoSec Medical Incorporated (NASDAQ:ONCS) saw 1.02 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $3.73 trading at -$0.19 or -4.85% at ring of the bell on the day assigns it a market valuation of $7.65M. That closing price of ONCS’s stock is … OncoSec Medical Incorporated (NASDAQ:ONCS) Falls -4.85%, But An Additional Plunge May Follow. Read More »
Is OncoSec Medical Incorporated (NASDAQ: ONCS) A Great Stock To Invest In? 2022/11/23 18:00:00 Stocks Register
OncoSec Medical Incorporated (NASDAQ:ONCS) traded at $3.90 at last check on Wednesday, November 23, made a downward move of -0.51% on its previous day’s price. Looking at the stock we see that its previous close was $3.92 and the beta (5Y monthly) reads 1.90 with the day’s price range being $3.91 – $6.4999. In terms … Is OncoSec Medical Incorporated (NASDAQ: ONCS) A Great Stock To Invest In? Read More »
Nasdaq - OncoSec Medical Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS 2022/06/15 13:15:08 Business Mag
OncoSec Medical issued its quarterly earnings results on Tuesday. The biotechnology company reported earnings per share for the quarter, topping the consensus estimate of by…
Robert Arch joins OncoSec Medical as CEO 2022/04/29 12:07:58 Seeking Alpha
OncoSec Medical (ONCS) has appointed Robert Arch as President and CEO.Arch has over 28 years of experience, extending from academia to the pharmaceutical industry
OncoSec appoints new finance chief 2022/02/23 10:41:17 Seeking Alpha
OncoSec Medical Incorporated (ONCS) has appointed George Chi as Chief Financial Officer. Mr
OncoSec Announces Appointment of George Chi as Chief Financial Officer 2022/02/22 22:59:00 Kwhen Finance
OncoSec Medical Inc Shares Close the Day 13.8% Higher - Daily Wrap 2022/01/14 07:30:28 Kwhen Finance
OncoSec Medical Inc (ONCS) shares closed today 13.8% higher than it did at the end of yesterday. The stock is currently down 10.3% year-to-date, down 86.7% over the past 12 months, and down 93.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $1.07 and as low as $0.82 this week.Shares closed 88.0% below its 52-week high and 22.5% above its 52-week low.Trading volume this week was 26.8% lower than the 10-day average and 68.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 93.7% The company's stock price performance over the past 12 months lags the peer average by 116.2%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.